Fig. 8
Clinical implications of circPINTexon2 and PINT87aa. a Expression of circPINTexon2 and PINT87aa in human glioma samples with different WHO grades and matched adjacent normal tissues. b Expression of circPINTexon2 and PINT87aa in breast cancer, hepatic cellular carcinoma, gastric cancer, and adjacent normal tissues. c Anti-cancer effects of PINT87aa in vivo; left, mice with brain xenograft tumors were sacrificed 60 days after implantation; right, Kaplan–Meier survival curves of mice implanted with 456 and 4121 cells stably overexpressing PINT87aa and their respective parental cells (N = 8 mice/treatment group, P < 0.001, two-tailed log-rank test). d Nude mice were subcutaneously injected with 5 × 106 Hs683 and SW1783 PINT87aa K.O. cells and their parental cells using Matrigel and were then monitored daily. Day 0 indicates the first day of injection. Tumor progression was monitored using a small animal imaging system or through caliper measurements. Error bars indicate standard error (N = 5 mice/treatment group, P < 0.01, two-tailed log-rank test)
